Angiotensinamide

Summary

Angiotensinamide (also known as hypertensin or angiotonin) is a synthetic form of angiotensin II (amide form) that was historically used as a vasopressor agent for the treatment of refractory hypotension and shock states. It was one of the earliest peptide-based vasopressors used clinically but has largely been replaced by catecholamines and other vasopressors.

Mechanism of Action

Directly activates angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cortex, causing potent vasoconstriction and aldosterone release, leading to increased systemic vascular resistance and blood pressure.

Routes of Administration

Goals & Uses

• Pharmacological research toolResearchHigh
• Vasopressor support in distributive shockHemodynamic SupportModerate
• Treatment of refractory hypotensionHemodynamic SupportModerate

Contraindications

• HypervolemiaFluid BalanceModerate
• HypertensionCardiovascularHigh
• Known hypersensitivity to angiotensin analogsAllergy/ImmunologyHigh

Adverse Effects

• Oliguria / renal impairmentRenalUncommon
• Hypertension / hypertensive crisisCardiovascularCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Hyperkalemia or hypokalemiaMetabolicUncommon
• BradycardiaCardiovascularCommon

Drug Interactions

• AT1 receptor blockers (ARBs)High
• Other vasopressors (e.g., norepinephrine, vasopressin)Moderate
• ACE inhibitorsModerate

Population Constraints

• PregnancyReproductive SafetyAbsolute
• Renal impairmentOrgan ImpairmentRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionWithdrawnPreviously marketed as Hypertensin in some European countries; no longer commercially available.
• United StatesWithdrawnAngiotensinamide is not currently approved in the US. Synthetic angiotensin II (giapreza) is separately approved but is a distinct product.
• United KingdomUnknownNo current marketing authorization known; historical use only.

Angiotensinamide was previously approved and marketed in some jurisdictions (notably Europe and parts of the Americas) under the brand name Hypertensin for vasopressor use. It is no longer widely commercially available and is considered largely withdrawn or discontinued in most markets. Synthetic angiotensin II has been re-investigated and re-approved in the US (as giapreza) but angiotensinamide specifically is not the same formulation.

Evidence & Sources

No sources recorded yet.